Patents by Inventor Zhiqian Zhang

Zhiqian Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnostic kit for metastasis and invasion of breast cancer and use of shRNA molecule for silencing expression of human LINC01614
    Patent number: 12286628
    Abstract: The invention provides a diagnostic kit for metastasis and invasion of breast cancer and a use of an shRNA molecule for silencing expression of human LINC01614. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.
    Type: Grant
    Filed: November 29, 2023
    Date of Patent: April 29, 2025
    Assignee: Zhejiang Chinese Medical University
    Inventors: Fangfang Tao, Zhiqian Zhang, Wenhong Liu, Ye Xu, Qingling Liu, Junfeng Li
  • DIAGNOSTIC KIT FOR METASTASIS AND INVASION OF BREAST CANCER AND USE OF shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614
    Publication number: 20240124880
    Abstract: The invention provides a diagnostic kit for metastasis and invasion of breast cancer and a use of an shRNA molecule for silencing expression of human LINC01614. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.
    Type: Application
    Filed: November 29, 2023
    Publication date: April 18, 2024
    Applicant: Zhejiang Chinese Medical University
    Inventors: Fangfang TAO, Zhiqian ZHANG, Wenhong LIU, Ye XU, Qingling LIU, Junfeng LI
  • Medication and diagnostic kit for inhibiting metastasis and invasion of breast cancer, shRNA molecule for silencing expression of human LINC01614 and application thereof
    Patent number: 11873492
    Abstract: The invention provides a medication and a diagnostic kit for inhibiting metastasis and invasion of breast cancer, an shRNA molecule for silencing expression of human LINC01614 and applications thereof. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: January 16, 2024
    Assignee: Zhejiang Chinese Medical University
    Inventors: Fangfang Tao, Zhiqian Zhang, Wenhong Liu, Ye Xu, Qingling Liu, Junfeng Li
  • MEDICATION AND DIAGNOSTIC KIT FOR INHIBITING METASTASIS AND INVASION OF BREAST CANCER, shRNA MOLECULE FOR SILENCING EXPRESSION OF HUMAN LINC01614 AND APPLICATION THEREOF
    Publication number: 20230174986
    Abstract: The invention provides a medication and a diagnostic kit for inhibiting metastasis and invasion of breast cancer, an shRNA molecule for silencing expression of human LINC01614 and applications thereof. The shRNAs obtained by the invention can interfere with the expression of LINC01614, thereby reducing the migration and invasion ability of tumor cells, inhibiting the expression of EMT proteins, and inhibiting tumor formation and lung metastasis in an animal model in vivo. The invention provides a new solution for targeted therapy of breast cancer. Therefore, the kit for diagnosing metastasis and invasion of breast cancer and the medication for treating metastasis and invasion of breast cancer are developed. The invention provides a new way and strategy for diagnosing and treating metastasis and invasion of breast cancer.
    Type: Application
    Filed: June 29, 2022
    Publication date: June 8, 2023
    Applicant: Zhejiang Chinese Medical University
    Inventors: Fangfang TAO, Zhiqian ZHANG, Wenhong LIU, Ye XU, Qingling LIU, Junfeng LI
  • ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF
    Publication number: 20200040097
    Abstract: Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immunizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.
    Type: Application
    Filed: January 3, 2019
    Publication date: February 6, 2020
    Applicant: Beijing Institute for Cancer Research
    Inventors: Zhiqian Zhang, Wei Zhao, Limin Wang, Haibo Han, Baocai Xing
  • Antibody and binding fragment recognizing CACNA2D1 and use thereof
    Patent number: 10174123
    Abstract: Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immunizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.
    Type: Grant
    Filed: February 22, 2012
    Date of Patent: January 8, 2019
    Assignee: Beijing Institute for Cancer Research
    Inventors: Zhiqian Zhang, Wei Zhao, Limin Wang, Haibo Han, Baocai Xing
  • ANTIBODY AND ANTIGEN RECOGNIZING TUMOR-INITIATING CELLS AND USE THEREOF
    Publication number: 20140044729
    Abstract: Disclosed is a method for searching, identifying, or validating a marker CACNA2D1 of tumor-initiating cells. The method comprises a step of immuninizing an animal using HEP-12 cells originating from a recurrent tumor and rich in originating cells. Also disclosed is a monoclonal antibody specially recognizing CACNA2D1 or antigen-binding fragments thereof, and the use thereof for treating or preventing tumors or diseases or conditions related to CACNA2D1.
    Type: Application
    Filed: February 22, 2012
    Publication date: February 13, 2014
    Applicant: BEIJING INSTITUTE FOR CANCER RESEARCH
    Inventors: Zhiqian Zhang, Wei Zhao, Limin Wang, Haibo Han, Baocai Xing